Lumateperone Added to Lithium or Valproate for Bipolar Depression
About this title
Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
Read the official source — NCT02600507Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Rogers and 70 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 529
- Sponsor
- Intra-Cellular Therapies, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Russia, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT02600507
- Official title
Show the full official title
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Rogers, United States · Cerritos, United States · Costa Mesa, United States
69 more locations
- Culver City, United States
- Garden Grove, United States
- Glendale, United States
- Lemon Grove, United States
- Oceanside, United States
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Santa Rosa, United States
- Sherman Oaks, United States
- Temecula, United States
- Jacksonville, United States
- Lauderhill, United States
- Miami, United States
- Orange City, United States
- Orlando, United States
- Atlanta, United States
- Savannah, United States
- Chicago, United States
- Lake Charles, United States
- Baltimore, United States
- O'Fallon, United States
- St Louis, United States
- Las Vegas, United States
- Berlin, United States
- Cherry Hill, United States
- Toms River, United States
- Cedarhurst, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Charlotte, United States
- Cincinnati, United States
- Dayton, United States
- Garfield Heights, United States
- Allentown, United States
- Philadelphia, United States
- The Woodlands, United States
- Everett, United States
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Lovech, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Moscow, Russia
- Nizhny Novgorod, Russia
- Omsk, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tomsk, Russia
- Belgrade, Serbia
- Kovin, Serbia
- Novi Sad, Serbia
- Šumadija, Serbia
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kropyvnytskyi, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Smila, Ukraine
- Vasylkiv, Ukraine
- Vinnytsia, Ukraine
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Intra-Cellular Therapies, Inc.
Did this study involve medication?
Yes. The study involved medication, including Lumateperone (ITI-007) and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
